Search alternatives:
marked decrease » marked increase (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
marked decrease » marked increase (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1
Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.
Published 2025“…<p>(A) Ki-67 expression in parathyroid glands of rats with CKD-induced sHPT treated with Cinacalcet either early in the inactive light phase (<i>Cina1</i>; N = 10) or early in the active dark phase (<i>Cina2</i>; N = 9) compared to untreated rats with sHPT investigated at similar time points (<i>PNX1</i>; N = 7 and <i>PNX2</i>; N = 7, respective) and to normal rats investigated at similar time points (<i>ctrl1</i>; N = 9 and <i>ctrl2</i>; N = 7, respective). …”
-
2
-
3
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…In addition, compound <b>E35</b> significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. Mechanistically, compound <b>E35</b> markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. …”
-
4
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…In addition, compound <b>E35</b> significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. Mechanistically, compound <b>E35</b> markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. …”
-
5
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…In addition, compound <b>E35</b> significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. Mechanistically, compound <b>E35</b> markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. …”
-
6
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…In addition, compound <b>E35</b> significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. Mechanistically, compound <b>E35</b> markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. …”
-
7
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…In addition, compound <b>E35</b> significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. Mechanistically, compound <b>E35</b> markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. …”
-
8
DataSheet1_Decreasing viscosity and increasing accessible load by replacing classical diluents with a hydrotrope in liquid–liquid extraction.docx
Published 2025“…We show that using hydrotropes as a diluent decreases the viscosity of solutions by more than a factor of ten, even under high load by extracted cations. …”
-
9
-
10
Overview of the WeARTolerance program.
Published 2024“…The quantitative results from Phase 1 demonstrated a decreasing trend in all primary outcomes. …”
-
11
-
12
-
13
-
14
-
15
-
16
Table_3_Loss of CDYL Results in Suppression of CTNNB1 and Decreased Endometrial Receptivity.docx
Published 2025“…<p>Impaired endometrial receptivity is one of the major causes of recurrent implantation failure (RIF), although the underlying molecular mechanism has not been fully elucidated. In the present study, we demonstrated that chromodomain Y like (CDYL) was highly expressed in the endometrium at mid-secretory phase during the normal menstrual cycles. …”
-
17
Image_4_Loss of CDYL Results in Suppression of CTNNB1 and Decreased Endometrial Receptivity.TIF
Published 2025“…<p>Impaired endometrial receptivity is one of the major causes of recurrent implantation failure (RIF), although the underlying molecular mechanism has not been fully elucidated. In the present study, we demonstrated that chromodomain Y like (CDYL) was highly expressed in the endometrium at mid-secretory phase during the normal menstrual cycles. …”
-
18
Image_1_Loss of CDYL Results in Suppression of CTNNB1 and Decreased Endometrial Receptivity.TIF
Published 2025“…<p>Impaired endometrial receptivity is one of the major causes of recurrent implantation failure (RIF), although the underlying molecular mechanism has not been fully elucidated. In the present study, we demonstrated that chromodomain Y like (CDYL) was highly expressed in the endometrium at mid-secretory phase during the normal menstrual cycles. …”
-
19
Image_3_Loss of CDYL Results in Suppression of CTNNB1 and Decreased Endometrial Receptivity.TIF
Published 2025“…<p>Impaired endometrial receptivity is one of the major causes of recurrent implantation failure (RIF), although the underlying molecular mechanism has not been fully elucidated. In the present study, we demonstrated that chromodomain Y like (CDYL) was highly expressed in the endometrium at mid-secretory phase during the normal menstrual cycles. …”
-
20
Image_8_Loss of CDYL Results in Suppression of CTNNB1 and Decreased Endometrial Receptivity.TIF
Published 2025“…<p>Impaired endometrial receptivity is one of the major causes of recurrent implantation failure (RIF), although the underlying molecular mechanism has not been fully elucidated. In the present study, we demonstrated that chromodomain Y like (CDYL) was highly expressed in the endometrium at mid-secretory phase during the normal menstrual cycles. …”